Products & Services
Five Chinese drugmakers licensed to make generic versions of Pfizer's new Crown oral drug
2023-01-09
Beijing time on March 18, Geneva Medicines Patent Pool (Medicines PatentPool, MPP) official website released news that has signed an agreement with 35 companies, these companies are allowed to produce generic Pfizer's new crown oral drug Paxlovid one of the components of the nirmatrelvir API (nirmatrelvir) or preparations.
The list includes five Chinese drug companies, namely Fosun Pharmaceuticals, Huahai Pharmaceuticals, Pulo Pharmaceuticals, Jiuzhou Pharmaceuticals, and Shanghai Diceno, of which Jiuzhou Pharmaceuticals only produces APIs, while the rest can produce both APIs and preparations.
Source: MPP official website
According to the official website, the Medicines Patent Pool (MPP) is a United Nations-supported public health organisation dedicated to increasing access to life-saving medicines in low- and middle-income countries and promoting drug development.
The authorisation comes after an announcement on 18 January that Pfizer had signed a voluntary licensing agreement with the Medicines Patent Pool (MPP) to help expand access to its medicines in 95 low- and middle-income countries, which account for about 53% of the world's population. However, the news did not reveal which companies were involved.
Paxlovid is an oral, small-molecule neocoronaviral therapeutic drug, specifically, a treatment consisting of a combination of PF-07321332 and ritonavir.On 11 February, the State Drug Administration (SDA) issued a news release stating that it had conditionally approved Pfizer's neocoronaviral therapeutic drug, Nematide, in accordance with the relevant provisions of the Drug Administration Law and in accordance with the special approval procedures for medicines for emergency review and approval. Weil tablets/ritonavir tablets combination package (i.e. Paxlovid) import registration.
This is not the first time that a Chinese pharmaceutical company has been authorised to copy an oral neocoronavirus drug. on 20 January, the Medicines Patent Pool (MPP) announced via its official website that it had signed agreements with 27 pharmaceutical companies to allow them to manufacture and supply Merck Sharp & Dohme's oral anti-neocoronavirus drug Molnupiravir to 105 low- and middle-income countries or regions around the world, in order to promote the drug's affordability and accessibility globally. Five Chinese pharmaceutical companies, including Fosun Pharmaceuticals, Borealis Pharmaceuticals, Shijiazhuang Longze Pharmaceuticals, Shanghai Diseno and Lanhua Pharmaceuticals, are among them, the first four of which are licensed to produce both APIs and finished products, and Lanhua Pharmaceuticals is licensed to produce APIs.
